Haematology

Multiple myeloma
#Arcellx #CAR-T #Cell therapy #Clinical trial #Haematology #Myeloma #Oncology #Phase I trial

CART-ddBCMA trial shows durable response in myeloma patients

Arcellx has revealed encouraging interim data from its Phase I study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The company plans to present new data with a median follow-up of 26.5 months at the 65th American Society of Hematology (ASH) Annual Meeting and… Read More

#Cancer Research #News

Blood cancer
#Bispecific Antibodies #Cancer research #Haematology #MHRA #Oncology #UK

New UK therapy option for hard-to-treat lymphoma

The MHRA has granted conditional marketing authorisation for Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The conditional marketing authorisation for Great Britain is based on the single-arm Phase I/II EPCORE NHL-1 trial… Read More

#News #Regulatory

Blood cells
#Artificial intelligence (AI) #Collaboration #Haematology #Intelligent OMICS #Janssen #Multi-omics #Oncology

Intelligent OMICS and Janssen enter AI research collaboration

AI drug discovery company Intelligent OMICS and Janssen Research & Development have agreed a target discovery collaboration to evaluate novel biological targets for the treatment of haematological cancers. The collaboration will combine Intelligent OMICS’ AI platform, which uses multi-omics data and deep learning algorithms to uncover therapeutic opportunities for treatment,… Read More

#Business & Investment #News

FDA
#Acute Myeloid Leukaemia #Daiichi Sankyo #FDA #Haematology #Leukaemia

FDA approves quizartinib for acute myeloid leukaemia

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive. It is approved with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following… Read More

#News #Regulatory

Bispecific antibodies
#AbbVie #Bispecific Antibodies #Cancer research #CHMP #EMA #Genmab #Haematology #Oncology

Bispecific antibody a “promising treatment option” for DLBCL

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The final… Read More

#News #Regulatory

Oncology Research Concept
#Cancer research #Drug discovery #Haematology #Oncology

Q&A with Mark Garner: The golden age of cancer research  

Mark Garner, PhD., Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research.  RA: Please can you tell us a bit more about your role at Agilent?   MG: I am… Read More

#Exclusive Content

Blood cells
#blood #Haematology #Phase III trial #Takeda #Trial data

Promising new drug for chronic blood clotting disorder

Takeda has revealed favourable interim results from its Phase III crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). cTTP is an ultra-rare, chronic and debilitating blood clotting disorder caused by a… Read More

#News